FDA 483 OBSERVATION · #802 OF 1,932 MOST-CITED

Records maintained concurrently

FDA cited this observation 24 times across 24 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation24
BY FISCAL YEAR
FY20261
FY20253
FY20246
FY20232
FY20221
FY20211
FY20193
FY20183
FY20173
FY20161

How FDA worded it — real examples

Records were not maintained concurrently with the performance of each step.

Amnion LLC · Sterling, Virginia · Human Tissue for Transplantation · 2026-04-08

Records were not maintained concurrently with the performance of each step.

Donor Services Laboratories Inc Tampa · Tampa, Florida · Human Tissue for Transplantation · 2025-09-12

Records were not maintained concurrently with the performance of each step.

Elite Orthopedics, LLC · Columbia, Missouri · Human Tissue for Transplantation · 2025-07-15

Records were not maintained concurrently with the performance of each step.

IndeCon, Inc. · Dallas, Texas · Human Tissue for Transplantation · 2024-12-12

Records were not maintained concurrently with the performance of each step.

University of Utah Cell Therapy and Regenerative Medicine · Salt Lake City, Utah · Human Tissue for Transplantation · 2024-09-30

Records were not maintained concurrently with the performance of each step.

Eurofins CellTx Inc · Tucson, Arizona · Human Tissue for Transplantation · 2024-09-20

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →